Literature DB >> 29554495

Cancer vaccines: translation from mice to human clinical trials.

Hoyoung Maeng1, Masaki Terabe1, Jay A Berzofsky2.   

Abstract

Therapeutic cancer vaccines have been a long-sought approach to harness the exquisite specificity of the immune system to treat cancer, but until recently have not had much success as single agents in clinical trials. However, new understanding of the immunoregulatory mechanisms exploited by cancers has allowed the development of approaches to potentiate the effect of vaccines by removing the brakes while the vaccines step on the accelerator. Thus, vaccines that had induced a strong T cell response but no clinical therapeutic effect may now reach their full potential. Here, we review a number of promising approaches to cancer vaccines developed initially in mouse models and their translation into clinical trials, along with combinations of vaccines with other therapies that might allow cancer vaccines to finally achieve clinical efficacy against many types of cancer. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29554495      PMCID: PMC5943163          DOI: 10.1016/j.coi.2018.03.001

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  122 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

3.  Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Authors:  Geoffrey T Gibney; Ragini R Kudchadkar; Ronald C DeConti; Melissa S Thebeau; Maria P Czupryn; Leticia Tetteh; Cabell Eysmans; Allison Richards; Michael J Schell; Kate J Fisher; Christine E Horak; H David Inzunza; Bin Yu; Alberto J Martinez; Ibrahim Younos; Jeffrey S Weber
Journal:  Clin Cancer Res       Date:  2014-12-18       Impact factor: 12.531

4.  Selective induction of high avidity CTL by altering the balance of signals from APC.

Authors:  SangKon Oh; James W Hodge; Jeffrey D Ahlers; Donald S Burke; Jeffrey Schlom; Jay A Berzofsky
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

5.  CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

Authors:  Edith M Janssen; Nathalie M Droin; Edward E Lemmens; Michael J Pinkoski; Steven J Bensinger; Benjamin D Ehst; Thomas S Griffith; Douglas R Green; Stephen P Schoenberger
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

6.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

Review 7.  Mutant ras epitopes as targets for cancer vaccines.

Authors:  S I Abrams; P H Hand; K Y Tsang; J Schlom
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

8.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Defining the critical hurdles in cancer immunotherapy.

Authors:  Bernard A Fox; Dolores J Schendel; Lisa H Butterfield; Steinar Aamdal; James P Allison; Paolo Antonio Ascierto; Michael B Atkins; Jirina Bartunkova; Lothar Bergmann; Neil Berinstein; Cristina C Bonorino; Ernest Borden; Jonathan L Bramson; Cedrik M Britten; Xuetao Cao; William E Carson; Alfred E Chang; Dainius Characiejus; A Raja Choudhury; George Coukos; Tanja de Gruijl; Robert O Dillman; Harry Dolstra; Glenn Dranoff; Lindy G Durrant; James H Finke; Jerome Galon; Jared A Gollob; Cécile Gouttefangeas; Fabio Grizzi; Michele Guida; Leif Håkansson; Kristen Hege; Ronald B Herberman; F Stephen Hodi; Axel Hoos; Christoph Huber; Patrick Hwu; Kohzoh Imai; Elizabeth M Jaffee; Sylvia Janetzki; Carl H June; Pawel Kalinski; Howard L Kaufman; Koji Kawakami; Yutaka Kawakami; Ulrich Keilholtz; Samir N Khleif; Rolf Kiessling; Beatrix Kotlan; Guido Kroemer; Rejean Lapointe; Hyam I Levitsky; Michael T Lotze; Cristina Maccalli; Michele Maio; Jens-Peter Marschner; Michael J Mastrangelo; Giuseppe Masucci; Ignacio Melero; Cornelius Melief; William J Murphy; Brad Nelson; Andrea Nicolini; Michael I Nishimura; Kunle Odunsi; Pamela S Ohashi; Jill O'Donnell-Tormey; Lloyd J Old; Christian Ottensmeier; Michael Papamichail; Giorgio Parmiani; Graham Pawelec; Enrico Proietti; Shukui Qin; Robert Rees; Antoni Ribas; Ruggero Ridolfi; Gerd Ritter; Licia Rivoltini; Pedro J Romero; Mohamed L Salem; Rik J Scheper; Barbara Seliger; Padmanee Sharma; Hiroshi Shiku; Harpreet Singh-Jasuja; Wenru Song; Per Thor Straten; Hideaki Tahara; Zhigang Tian; Sjoerd H van Der Burg; Paul von Hoegen; Ena Wang; Marij Jp Welters; Hauke Winter; Tara Withington; Jedd D Wolchok; Weihua Xiao; Laurence Zitvogel; Heinz Zwierzina; Francesco M Marincola; Thomas F Gajewski; Jon M Wigginton; Mary L Disis
Journal:  J Transl Med       Date:  2011-12-14       Impact factor: 5.531

View more
  16 in total

1.  Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model.

Authors:  Ashkan Safavi; Amirhosein Kefayat; Elham Mahdevar; Fatemeh Ghahremani; Navid Nezafat; Mohammad Hossein Modarressi
Journal:  Hum Vaccin Immunother       Date:  2020-06-04       Impact factor: 3.452

Review 2.  The p53 Saga: Early Steps in the Development of Tumor Immunotherapy.

Authors:  Albert B DeLeo; Ettore Appella
Journal:  J Immunol       Date:  2020-05-01       Impact factor: 5.422

Review 3.  Therapeutic cancer vaccine: building the future from lessons of the past.

Authors:  T Tran; C Blanc; C Granier; A Saldmann; C Tanchot; Eric Tartour
Journal:  Semin Immunopathol       Date:  2018-07-05       Impact factor: 9.623

Review 4.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

5.  Phototherapy using immunologically modified carbon nanotubes to potentiate checkpoint blockade for metastatic breast cancer.

Authors:  Yong Li; Xiaosong Li; Austin Doughty; Connor West; Lu Wang; Feifan Zhou; Robert E Nordquist; Wei R Chen
Journal:  Nanomedicine       Date:  2019-03-04       Impact factor: 5.307

Review 6.  Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.

Authors:  Aswathy R Devan; Bhagyalakshmi Nair; Ayana R Kumar; Balachandran S Vinod; Lekshmi R Nath
Journal:  Mol Biol Rep       Date:  2021-10-20       Impact factor: 2.316

7.  Enhanced development of functional human NK cells in NOD-scid-IL2rgnull mice expressing human IL15.

Authors:  Ken-Edwin Aryee; Lisa M Burzenski; Li-Chin Yao; James G Keck; Dale L Greiner; Leonard D Shultz; Michael A Brehm
Journal:  FASEB J       Date:  2022-09       Impact factor: 5.834

Review 8.  Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Authors:  Zong Sheng Guo; Binfeng Lu; Zongbi Guo; Esther Giehl; Mathilde Feist; Enyong Dai; Weilin Liu; Walter J Storkus; Yukai He; Zuqiang Liu; David L Bartlett
Journal:  J Immunother Cancer       Date:  2019-01-09       Impact factor: 13.751

Review 9.  Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.

Authors:  Alice Mougel; Magali Terme; Corinne Tanchot
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

10.  Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy.

Authors:  Lei Qin; Shuya Wang; Donye Dominguez; Alan Long; Siqi Chen; Jie Fan; Jihae Ahn; Kacper Skakuj; Ziyin Huang; Andrew Lee; Chad Mirkin; Bin Zhang
Journal:  Front Immunol       Date:  2020-07-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.